New York-based private equity player OrbiMed Advisors raised $160 million for its Healthcare Fund Management division, according to regulatory filings submitted this month.
OrbiMed, which invests in the life science space, listed the raise under 1 unnamed investor and through a combination of equity and "pooled investment fund interests" offered, according to the filing.
The fund group has had a good run of late, having in August registered a $300 million fund to invest in healthcare companies in Asia. The company in 2012 closed a $222 million fund aimed at the Israeli life science market.
OrbiMed manages about $7 billion in assets, cementing its rank as the top healthcare-dedicated investment firm in the world, according to the company’s bio. Among its portfolio companies are CardiAQ, InspireMD (OTC:NSPR), Insulet (NSDQ:PODD), NxStage Medical (NSDQ:NXTM) and Response Biomedical (TSE:RBM).